[1]
Quirke VM. Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation. Frontiers in pharmacology. 2017:8():620. doi: 10.3389/fphar.2017.00620. Epub 2017 Sep 12
[PubMed PMID: 28955226]
Level 3 (low-level) evidence
[2]
Brufsky AM, Dickler MN. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. The oncologist. 2018 May:23(5):528-539. doi: 10.1634/theoncologist.2017-0423. Epub 2018 Jan 19
[PubMed PMID: 29352052]
[3]
Eggemann H, Altmann U, Costa SD, Ignatov A. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. Journal of cancer research and clinical oncology. 2018 Feb:144(2):337-341. doi: 10.1007/s00432-017-2539-7. Epub 2017 Nov 2
[PubMed PMID: 29098396]
[4]
Gradishar W, Salerno KE. NCCN Guidelines Update: Breast Cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2016 May:14(5 Suppl):641-4
[PubMed PMID: 27226503]
[5]
Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast (Edinburgh, Scotland). 2014 Oct:23(5):546-51. doi: 10.1016/j.breast.2014.06.015. Epub 2014 Jul 9
[PubMed PMID: 25023044]
Level 1 (high-level) evidence
[6]
Sauter ER. Breast Cancer Prevention: Current Approaches and Future Directions. European journal of breast health. 2018 Apr:14(2):64-71. doi: 10.5152/ejbh.2018.3978. Epub 2018 Apr 1
[PubMed PMID: 29774312]
Level 3 (low-level) evidence
[7]
Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004 Feb 1:100(3):612-20
[PubMed PMID: 14745880]
[8]
Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Jan 15:19(2):364-7
[PubMed PMID: 11208827]
[9]
Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W, Gynecologic Oncology Group study. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology. 2004 Jan:92(1):10-4
[PubMed PMID: 14751131]
[10]
Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Feb 1:23(4):808-15
[PubMed PMID: 15681525]
[11]
Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Human reproduction (Oxford, England). 2005 Jun:20(6):1511-5
[PubMed PMID: 15845599]
Level 1 (high-level) evidence
[12]
Adamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertility and sterility. 2003 Oct:80(4):914-20
[PubMed PMID: 14556812]
[13]
Clarke SC, Schofield PM, Grace AA, Metcalfe JC, Kirschenlohr HL. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation. 2001 Mar 20:103(11):1497-502
[PubMed PMID: 11257075]
[14]
Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991 Jul 15:68(2):269-71
[PubMed PMID: 2070324]
[15]
Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecologic oncology. 1996 Jul:62(1):4-6
[PubMed PMID: 8690289]
[16]
Dellagrammaticas D, Bryden AA, Collins GN. Regression of metastatic transitional cell carcinoma in response to tamoxifen. The Journal of urology. 2001 May:165(5):1631
[PubMed PMID: 11342939]
[17]
Yang CH, Cheng AL, Yeh KH, Yu CJ, Lin JF, Yang PC. High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma. Cancer. 1999 Aug 1:86(3):415-20
[PubMed PMID: 10430249]
[18]
Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A, Normandeau R, Jones A. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study. Cancer. 1990 May 1:65(9):1895-902
[PubMed PMID: 2164872]
[19]
Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH, McCune-Albright Study Group. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. The Journal of pediatrics. 2003 Jul:143(1):60-6
[PubMed PMID: 12915825]
Level 1 (high-level) evidence
[20]
Beguerie JR, Xingzhong J, Valdez RP. Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis. International journal of dermatology. 2010 Oct:49(10):1194-202. doi: 10.1111/j.1365-4632.2010.04529.x. Epub
[PubMed PMID: 20883410]
Level 1 (high-level) evidence
[21]
O'Day SJ, Boasberg PD, Kristedja TS, Martin M, Wang HJ, Fournier P, Cabot M, DeGregorio MW, Gammon G. High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma. Cancer. 2001 Aug 1:92(3):609-19
[PubMed PMID: 11505406]
[22]
McClay EF, McClay ME, Monroe L, Baron PL, Cole DJ, O'Brien PH, Metcalf JS, Maize JC. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. British journal of cancer. 2000 Jul:83(1):16-21
[PubMed PMID: 10883662]
[23]
McKeage MJ, Lorentzos A, Gore ME. Tamoxifen and chemotherapy for refractory metastatic malignant melanoma. The New England journal of medicine. 1993 Jan 14:328(2):140-1
[PubMed PMID: 8416433]
[24]
Ricciardi I, Ianniruberto A. Tamoxifen-induced regression of benign breast lesions. Obstetrics and gynecology. 1979 Jul:54(1):80-4
[PubMed PMID: 377165]
[25]
Taetle R, Mendelsohn J, Green MR. Hypercalcemia and tamoxifen readministered. Annals of internal medicine. 1978 Aug:89(2):287
[PubMed PMID: 677600]
[26]
Moertel CG, Engstrom PF, Schutt AJ. Tamoxifen therapy for metastatic carcinoid tumor: a negative study. Annals of internal medicine. 1984 Apr:100(4):531-2
[PubMed PMID: 6200021]
[27]
Cvancara JL, Meffert JJ, Elston DM. Estrogen-sensitive cutaneous polyarteritis nodosa: response to tamoxifen. Journal of the American Academy of Dermatology. 1998 Oct:39(4 Pt 1):643-6
[PubMed PMID: 9777776]
[28]
Fraser IS. Menorrhagia due to myometrial hypertrophy: treatment with tamoxifen. Obstetrics and gynecology. 1987 Sep:70(3 Pt 2):505-6
[PubMed PMID: 3627613]
[29]
Markwalder TM, Seiler RW, Zava DT. Antiestrogenic therapy of meningiomas--a pilot study. Surgical neurology. 1985 Sep:24(3):245-9
[PubMed PMID: 4023903]
Level 3 (low-level) evidence
[30]
Serels S, Melman A. Tamoxifen as treatment for gynecomastia and mastodynia resulting from hormonal deprivation. The Journal of urology. 1998 Apr:159(4):1309
[PubMed PMID: 9507867]
[31]
Fentiman IS, Caleffi M, Hamed H, Chaudary MA. Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial. The British journal of surgery. 1988 Sep:75(9):845-6
[PubMed PMID: 3052691]
[32]
Grio R, Cellura A, Geranio R, Porpiglia M, Piacentino R. [Clinical efficacy of tamoxifen in the treatment of premenstrual mastodynia]. Minerva ginecologica. 1998 Mar:50(3):101-3
[PubMed PMID: 9595924]
[33]
Li CP, Lee FY, Hwang SJ, Chang FY, Lin HC, Kuo BI, Chu CJ, Lee SD. Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study. The American journal of gastroenterology. 2000 Apr:95(4):1051-5
[PubMed PMID: 10763958]
Level 1 (high-level) evidence
[34]
Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbøl I, Mouridsen HT. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 May:12(5):992-7
[PubMed PMID: 8164053]
Level 1 (high-level) evidence
[35]
Taçyildiz N, Yavuz G, Unal E, Gündüz K, Günalp I, Ekinci C. Encouraging result of tamoxifen in a retinoblastoma patient with central nervous system metastasis. Pediatric hematology and oncology. 2003 Sep:20(6):473-6
[PubMed PMID: 14631622]
[36]
De M, Jaap A, Dempster J. Tamoxifen therapy in steroid resistant Reidel's thyroiditis. Scottish medical journal. 2001 Apr:46(2):56-7
[PubMed PMID: 11394342]
[37]
Lissoni P, Paolorossi F, Tancini G, Ardizzoia A, Barni S, Brivio F, Maestroni GJ, Chilelli M. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. British journal of cancer. 1996 Nov:74(9):1466-8
[PubMed PMID: 8912546]
[38]
Lee WL, Cheng MH, Chao HT, Wang PH. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Taiwanese journal of obstetrics & gynecology. 2008 Mar:47(1):24-31. doi: 10.1016/S1028-4559(08)60051-0. Epub
[PubMed PMID: 18400579]
[39]
Neyman A, Eugster EA. Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017. Pediatric endocrinology reviews : PER. 2017 Dec:15(2):136-141. doi: 10.17458/per.vol15.2017.nau.treatmentgirlsboys. Epub
[PubMed PMID: 29292624]
[40]
Taniguchi-Takizawa T, Kato N, Shimizu M, Kume T, Yamazaki H. Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes. Drug metabolism and pharmacokinetics. 2021 Oct:40():100412. doi: 10.1016/j.dmpk.2021.100412. Epub 2021 Jun 25
[PubMed PMID: 34352706]
[41]
Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Jul 20:32(21):2255-69. doi: 10.1200/JCO.2013.54.2258. Epub 2014 May 27
[PubMed PMID: 24868023]
Level 1 (high-level) evidence
[42]
Bratherton DG, Brown CH, Buchanan R, Hall V, Kingsley Pillers EM, Wheeler TK, Williams CJ. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. British journal of cancer. 1984 Aug:50(2):199-205
[PubMed PMID: 6380554]
[43]
Buttiron Webber T, Marra D, Puntoni M, Giuliano S, Briata IM, Cevasco I, Clavarezza M, D'Amico M, Defferrari C, Gozza A, Provinciali N, Lazzeroni M, Bonanni B, DeCensi A. Patient- versus physician-reported outcomes in a low-dose tamoxifen trial in noninvasive breast cancer. The breast journal. 2021 Nov:27(11):817-823. doi: 10.1111/tbj.14296. Epub 2021 Oct 8
[PubMed PMID: 34626060]
[44]
Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009 Oct 1:115(19):4442-9. doi: 10.1002/cncr.24508. Epub
[PubMed PMID: 19569248]
[45]
Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Journal of the National Cancer Institute. 1994 Apr 6:86(7):527-37
[PubMed PMID: 8133536]
[46]
Yang G, Nowsheen S, Aziz K, Georgakilas AG. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacology & therapeutics. 2013 Sep:139(3):392-404. doi: 10.1016/j.pharmthera.2013.05.005. Epub 2013 May 24
[PubMed PMID: 23711794]
[47]
Mulvenna PM, Wright AJ, Podd TJ. Life-threatening tamoxifen-induced hypercalcaemia. Clinical oncology (Royal College of Radiologists (Great Britain)). 1999:11(3):193-5
[PubMed PMID: 10465476]
[48]
Manish M, Lynn AM, Mishra S. Cytochrome P450 2C9 polymorphism: Effect of amino acid substitutions on protein flexibility in the presence of tamoxifen. Computational biology and chemistry. 2020 Feb:84():107166. doi: 10.1016/j.compbiolchem.2019.107166. Epub 2019 Nov 17
[PubMed PMID: 31785970]
[49]
Antunes MV, Timm TA, de Oliveira V, Staudt DE, Raymundo S, Gössling G, Biazús JV, Cavalheiro JA, Rosa DD, Wallemacq P, Haufroid V, Linden R, Schwartsmann G. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation. Therapeutic drug monitoring. 2015 Dec:37(6):733-44. doi: 10.1097/FTD.0000000000000212. Epub
[PubMed PMID: 25853922]
[51]
Singh HK, Prasad MS, Kandasamy AK, Dharanipragada K. Tamoxifen-induced hypertriglyceridemia causing acute pancreatitis. Journal of pharmacology & pharmacotherapeutics. 2016 Jan-Mar:7(1):38-40. doi: 10.4103/0976-500X.179365. Epub
[PubMed PMID: 27127396]
[52]
Givens CB, Bullock LN, Franks AS. Safety of concomitant tamoxifen and warfarin. The Annals of pharmacotherapy. 2009 Nov:43(11):1867-71. doi: 10.1345/aph.1M176. Epub 2009 Oct 20
[PubMed PMID: 19843839]
[54]
Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast cancer research and treatment. 2000 Mar:60(2):167-72
[PubMed PMID: 10845279]